[1] Borai A, Livingstone C, Ferns GAA. The biochemical assessment of insulin resistance. Ann Clin Biochem, 2007; 44, 324−42. doi:  10.1258/000456307780945778
[2] Gutch M, Kumar S, Razi S, et al. Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab, 2015; 19, 160−4. doi:  10.4103/2230-8210.146874
[3] Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest, 2000; 106, 453−8. doi:  10.1172/JCI10762
[4] Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk, 1996; 3, 213−9.
[5] Jayanthi R, Srinivasan AR, Niranjan G. Gene polymorphism of adiponectin SNP+ 45 with reference to thyroid status - a comparative study among non-obese, overweight and obese type 2 diabetics. J Obese Weight-Loss Medic, 2018; 4, 020.
[6] Jayanthi R, Srinivasan AR, Gopal N, et al. Association of divalent cations and insulin resistance with thyroid hormones in patients with type 2 diabetes mellitus. Diabetes Metab Syndr:Clin Res Rev, 2017; 11, S885−90. doi:  10.1016/j.dsx.2017.07.010
[7] Biswas D, Vettriselvi V, Choudhury J, et al. Adiponectin gene polymorphism and its association with type 2 diabetes mellitus. Indian J Clin Biochem, 2011; 26, 172−7. doi:  10.1007/s12291-011-0123-5
[8] Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28, 412−9. doi:  10.1007/BF00280883
[9] Frithioff-Bøjsøe C, Lund MAV, Lausten-Thomsen U, et al. Leptin, adiponectin, and their ratio as markers of insulin resistance and cardiometabolic risk in childhood obesity. Pediatr Diabetes, 2020; 21, 194−202. doi:  10.1111/pedi.12964
[10] Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci, 2017; 18, 1321. doi:  10.3390/ijms18061321